Gaetano Guglielmino - 22 Jan 2026 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Chief Commercial Officer
Issuer ticker: TMCI
Reported as of: 22 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2026, 21:30:09 UTC
Prior SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Gaetano Guglielmino

Key filing fact

Gaetano Guglielmino filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 23 Jan 2026.

Key facts

This page summarizes Gaetano Guglielmino's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jan 2026, 21:30.

Change

Previous filing in this sequence was filed on 03 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002047624 Primary reporting owner

Guglielmino Gaetano

Relationship: Chief Commercial Officer
Address: 100 PALMETTO PARK PLACE, PONTE VEDRA
Signature: /s/ Lisa Taylor as Attorney-in-fact for Gaetano Guglielmino
Signature date: 23 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Award

Transaction value: $0
Shares: +150,000
Change %: +44%
Price: $0.000000
Shares after: 490,901
Date: 22 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date.

Footnote F2

Includes 422,250 restricted stock units.